GlassScriptPhysician profile
Richard Cain
NPI 1700236510
$6,844.33
in general payments reported to CMS, 2019-2025
34 companies · $1,211 in 2025
The $1,211 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,285 · 2022: $1,471 · 2023: $1,410 · 2024: $1,468 · 2025: $1,211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,088.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $955.52 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $736.10 | 2022-2025 | |
| Novo Nordisk INC | $687.66 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $503.84 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $423.30 | 2021-2025 | |
| Mylan Specialty L.P. | $356.85 | 2021-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $325.62 | 2021-2024 | |
| Lilly USA, LLC | $298.89 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $289.05 | 2021-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $260.59 | 2021-2024 | Verquvo, Belsomra, Lagevrio |
| Paratek Pharmaceuticals, INC. | $249.85 | 2021-2023 | Nuzyra |
| Sumitomo Pharma America, INC. | $231.38 | 2023-2025 | Gemtesa |
| Amgen INC. | $176.43 | 2021-2025 | Otezla, Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $146.49 | 2021-2022 | |
| Pfizer INC. | $143.34 | 2021-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $131.26 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Sunovion Pharmaceuticals INC. | $119.58 | 2022 | |
| Dexcom, INC. | $110.12 | 2022-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $97.05 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.63 | 2021-2024 | Jardiance, Synjardy, Tradjenta |
| Viatris Specialty LLC | $79.32 | 2025 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $65.80 | 2022-2023 | Eliquis |
| Otsuka America Pharmaceutical, INC. | $64.68 | 2023-2025 | Rexulti |
| Inspire Medical Systems, INC. | $48.19 | 2025 | Inspire |
| Biohaven Pharmaceutical Holding Company LTD. | $47.04 | 2022 | |
| Astellas Pharma US INC | $38.65 | 2021 | |
| Calliditas Therapeutics US INC. | $27.33 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $26.55 | 2021-2025 | Zoryve |
| Radius Health, INC. | $23.68 | 2021 | |
| Lundbeck LLC | $22.50 | 2023 | Rexulti |
| Sun Pharmaceutical Industries INC. | $21.12 | 2021 | |
| Esperion Therapeutics, INC. | $17.25 | 2022 | |
| Sanofi-Aventis U.S. LLC | $12.72 | 2021 | |
| Nestle Healthcare Nutrition INC. | $11.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Cain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.